Hu et al. reported that ARID1A deficiency could increase tumor mutation burden, upregulate the programmed cell death ligand 1 (PD-L1) expression, and modulate the immune microenvironment [32], which supports our findings. This evidence concerns the gene CD274 and neoplasm.